Clinical Trials Logo

Clinical Trial Summary

Infective endocarditis (IE) is associated with an overall in-hospital mortality rate of 15-25% and a high incidence of embolic events (20-50%). Leading causes of mortality are heart failure (HF) resulting from valve dysfunction, and stroke caused by vegetation embolization. The rate of symptomatic embolic events occurring after antibiotic initiation is around 15%. Valve surgery benefit has been clearly demonstrated in patients with periannular complications and moderate to severe HF resulting from acute valve regurgitation. The timing of surgery to prevent embolism is critical since the risk of new embolic event is highest during the first weeks of antibiotic treatment. The primary objective is to compare clinical outcomes of Early Valve Surgery (as soon as possible within 72 hours of randomization) with those of a conventional management based on current guidelines in patients with native left-sided IE and high risk of embolism. 208 patients (104 patients per arm) will be included in a national multicenter (21 centers) prospective randomized open blinded end-point (PROBE) sequential superiority trial.


Clinical Trial Description

Infective endocarditis (IE) is associated with an overall in-hospital mortality rate of 15-25% and a high incidence of embolic events (20-50%). Leading causes of mortality are heart failure (HF) resulting from valve dysfunction, and stroke caused by vegetation embolization. The rate of symptomatic embolic events occurring after antibiotic initiation is around 15%. Valve surgery benefit has been clearly demonstrated in patients with periannular complications and moderate to severe HF resulting from acute valve regurgitation. Indications of valve surgery for prevention of embolic complications are less clearly defined. Potential complications of valve surgery and of implanted permanent prosthetic valve are to be balanced against their potential benefits in terms of prevented embolism and improved survival. The timing of surgery to prevent embolism is critical since the risk of new embolic event is highest during the first weeks of antibiotic treatment. The points in favor of early valve surgery (EVS) in patients with high embolic risk include the following 1) patients with high risk of embolism are identified by transesophageal echocardiography (TOE); 2) advances in surgical management of IE dramatically lowered postoperative mortality; 3) 2015 European ESC IE guidelines state that valve surgery should be performed in IE with vegetation above 10 mm AND an embolic event occurring while patients are receiving antibiotic (grade I/B) and should be considered in IE with vegetation above 30 mm (Grade IIaB ) and may be above 10 mm and severe valve regurgitation. The primary objective is to compare clinical outcomes of EVS (as soon as possible within 72 hours of randomization) with those of a conventional management based on current 2015 European ESC guidelines in patients with native left-sided IE and high risk of embolism. The primary assessment criterion is a composite of all-cause death and clinically symptomatic embolic events within 6 weeks from randomization in all included patient. 208 patients (104 patients per arm) will be included in a national multicenter (21 centers) prospective randomized open blinded end-point (PROBE) sequential superiority trial. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03718052
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Xavier DUVAL
Phone 140257135
Email xavier.duval@aphp.fr
Status Recruiting
Phase N/A
Start date April 11, 2019
Completion date April 11, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05547607 - Clinical and Diagnostic Features of Endocarditis
Completed NCT00750373 - Early Surgery Versus Conventional Treatment in Infective Endocarditis Phase 4
Recruiting NCT03690076 - Human Cardiac Mitochondria in Acute Endocarditis and Obesity
Terminated NCT01734694 - Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients Phase 4
Terminated NCT00995384 - Cardiac Computed Tomography (CT) Scan Compared to Transesophageal Echocardiogram (TEE) in Endocarditis N/A
Completed NCT04309591 - Cytosorb Therapy in Cardiac Surgery
Recruiting NCT05142891 - Renal Tolerance of Amoxicillin and Cloxacillin Combination
Recruiting NCT05703022 - Early Exercise Training in Patients Following Heart Valve Surgery for Infective Endocarditis. N/A
Completed NCT01431326 - Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Completed NCT03377465 - Biomarkers, Hemodynamic and Echocardiographic Predictors of Ischemic Strokes and Their Influence on the Course and Prognosis N/A
Recruiting NCT03892174 - Cytokine REmoval in CRitically Ill pAtients Requiring Surgical Therapy for Infective Endocarditis (RECReATE) N/A
Completed NCT03695861 - Contribution of 18F-FDG PET-CT in the Diagnosis and the Detection of Peripheral Emboli of Infectious Endocarditis on Native Valves N/A
Recruiting NCT02759978 - Individualized Diagnosis of Endocarditis and Its Therapy With a Focus on Infected Prosthetic materiAL
Completed NCT00709358 - Diagnosis of Septicaemia by Detection of Microbial DNA in Blood in Severe Infections Phase 4
Terminated NCT03148756 - Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis Phase 2
Enrolling by invitation NCT05156437 - Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) Phase 4
Recruiting NCT06107309 - Suppressive Antibiotic Therapy for Endocarditis
Completed NCT02251262 - Diagnostic Accuracy of 18FDG-PET-CT for Pacing or Defibrillation Lead Infection N/A
Recruiting NCT03112356 - The Value of 99mTc-Leukoscan® Scintigraphy in the Diagnosis of Infectious Endocarditis on Surgical Materials Phase 4
Completed NCT01375257 - Partial Oral Treatment of Endocarditis Phase 4